New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
10:31 EDTEVEP, ABB, LNCO, LINE, NSR, NUAN, HPT, FNP, CCJ, CYTX, DOX, SYMC, MEMPOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Cytori Therapeutics (CYTX) initiated with a Buy at Ascendiant Capital... Hospitality Properties (HPT) initiated with a Market Perform at JMP Securities... Memorial Production (MEMP) initiated with a Buy at Wunderlich... Roadrunner (RRTS) initiated with a Buy at Deutsche Bank... Cameco (CCJ) initiated with a Buy at Cantor... Symantec (SYMC) initiated with a Buy at B. Riley Caris... Nuance (NUAN) initiated with a Neutral at B. Riley Caris... NeuStar (NSR) initiated with a Neutral at B. Riley Caris... Fifth & Pacific (FNP) initiated with a Buy at BB&T... Amdocs (DOX) initiated with a Neutral at B. Riley Caris... EV Energy (EVEP) initiated with an Overweight at JPMorgan... LinnCo (LNCO) initiated with an Overweight at JPMorgan... LINN Energy (LINE) initiated with an Overweight at JPMorgan... ABB (ABB) initiated with an Outperform at Credit Suisse.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 25, 2015
06:10 EDTMEMPMemorial Production sees FY15 total net average daily production 249-265 MMcfe/d
Sees FY15 oil average daily production 10.3-11 MBbls/d. Sees FY15 NGLs average daily production of 8.5-9. MBbls/d. Sees FY15 natural gas average daily production of 136-145 MMcf/d.
06:10 EDTMEMPMemorial Production reports Q4 average daily production up 9% to 227.8 MMcfe
Subscribe for More Information
February 24, 2015
10:00 EDTMEMPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:17 EDTCYTXCytori Therapeutics receives positive European opinion on orphan drug status
Subscribe for More Information
07:30 EDTLINEJPMorgan to hold a conference
Global High Yield & Leveraged Finance Conference is being held in Miami Beach, FL on February 23-25 with webcasted company presentations to begin on February 24 at 7:40 am; not all company presentations may be webcasted. Webcast Link
06:26 EDTMEMPMemorial Production acquires oil and gas properties
Memorial Production announced that it has consummated a transaction with Memorial Resource Development Corp. whereby MRD exchanged its East Texas and non-core Louisiana properties for all of MEMP's interests in the Terryville Field in North Louisiana and cash consideration of approximately $78M, subject to customary purchase price adjustments. Terms of the transaction were approved by the board of the general partner of MEMP and by the board's conflicts committee, which was comprised entirely of independent directors. The transaction closed on February 23, 2015 and has an effective date of January 1, 2015. MRD will receive, in addition to the cash consideration, all of MEMP's position in the Terryville Field in North Louisiana, which includes interests in 5.1 net wells. Total proved reserves are estimated to be approximately 20 Bcfe and estimated December 2014 net production was approximately 5 MMcfe/d. In exchange, MEMP will receive properties primarily located in the Joaquin Field in Shelby and Panola counties in East Texas. The acquired properties consist of 165.3 net wells in East Texas and West Louisiana. MEMP will operate approximately 71% of the acquired producing wells. The transaction is expected to be immediately accretive to distributable cash flow and net asset value, estimated net proved reserves of 267 Bcfe, estimated December net production of 27 MMcfe/d, and proved reserve to production ratio of 27 years.
06:01 EDTMEMPMemorial Production upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Memorial Production Partners to Overweight saying the company's distribution looks sustainable. The firm raised its price target for shares to $18 from $16.
February 23, 2015
10:15 EDTSYMCCyberArk sinks after JPMorgan analyst cuts rating to sell
Subscribe for More Information
05:54 EDTSYMCSymantec management to meet with JMP Securities
Subscribe for More Information
February 20, 2015
17:03 EDTLNCOLinnCo files to sell common shares, no amount given
Subscribe for More Information
February 19, 2015
08:34 EDTSYMCIntralinks expands Enterprise Fabric partner ecosystem
Subscribe for More Information
07:22 EDTLINELINN Energy reports FY15 average daily production up 47% to 1,210 MMcfe/d
07:22 EDTLINELINN Energy reports Q4 average daily production up 53% to 1,358 MMcfe/d
Subscribe for More Information
07:06 EDTLINELINN Energy sees FY15 average production 1,090 MMcfe/d–1,200 MMcfe/d
Subscribe for More Information
07:04 EDTLINELINN Energy reports Q4 EPS (47c), consensus 6c
Subscribe for More Information
February 18, 2015
15:35 EDTLINE, LNCONotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Wal-Mart (WMT), consensus $1.54... Priceline (PCLN), consensus $10.10... DIRECTV (DTV), consensus $1.40... Noble Energy (NBL), consensus 35c... Host Hotels & Resorts (HST), consensus 39c... Hormel Foods (HRL), consensus 64c... Discovery Communications (DISCA), consensus 41c... SCANA (SCG), consensus 73c... Quanta Services (PWR), consensus 51c... Patterson (PDCO), consensus 59c... Denbury Resources (DNR), consensus 23c... T-Mobile (TMUS), consensus 5c... Linn Energy (LINE), consensus 6c... Linn Co (LNCO), consensus 39c... Bloomin' Brands (BLMN), consensus 27c... Huntington Ingalls (HII), consensus $1.98.
11:46 EDTNUANNuance management to meet with Wedbush
Meetings to be held in Chicago on February 23 and in Milwaukee on February 24 hosted by Wedbush.
February 17, 2015
08:34 EDTSYMCImprivata announces partnership with Symantec
Subscribe for More Information
08:03 EDTCYTXCytori Therapeutics begins enrollment in Phase II ACT-OA trial
Cytori Therapeutics announced that the first patient has been treated in its FDA approved trial assessing the effect of Cytori Cell Therapy for osteoarthritis of the knee. The patient was treated by Dr. Peter Hanson, Medical Director of Orthopedic Surgery at Sharp Grossmont Hospital. ACT-OA is a Phase II FDA approved randomized, double-blind, placebo controlled trial in 90 patients evaluating the efficacy and safety of Cytori’s autologous adipose derived therapy ECCO-50 (Cytori’s therapeutic under study). The trial tests both a low dose and a high dose vs. placebo and will be conducted over 48 weeks. The randomization will be 1:1:1 between the control, low dose and high dose groups. The primary end point will be pain on walking as measured by the Knee Injury and Osteoarthritis Outcome Score at 12 weeks. Secondary endpoints assessed will include pain, joint function, magnetic resonance imaging and adverse events.
07:22 EDTSYMCMitsubishi UFJ to hold a tour
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use